Biofrontera

BFRI · NASDAQ

$0.804−$0.0017 (−0.21%)TodayMarket closed · Oct 20, 7:25 PM ET

Prev close $0.8057

Latest news

Press releaseOct 8, 9:22 AM ETGlobe Newswire
Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body
NewsSep 28, 8:47 AM ET
Transcript: Biofrontera Q2 2026 Earnings Conference Call
Press releaseSep 14, 9:26 AM ETGlobe Newswire
Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
Press releaseAug 13, 8:51 AM ETGlobe Newswire
Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth
NewsMay 14, 11:39 AM ET
Transcript: Biofrontera Q1 2026 Earnings Conference Call
Press releaseMay 14, 7:30 AM ETGlobe Newswire
Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update
NewsMay 14, 7:11 AM ET
Earnings Scheduled For May 14, 2026
Press releaseMay 8, 4:00 PM ETGlobe Newswire
Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026
NewsMar 19, 5:49 PM ET
Biofrontera Q4 EPS $0.48 Beats $0.20 Estimate, Sales $17.100M Beat $16.146M Estimate
Press releaseMar 19, 9:25 AM ETGlobe Newswire
Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
NewsMar 19, 7:11 AM ET
Earnings Scheduled For March 19, 2026
Press releaseMar 9, 5:25 PM ETGlobe Newswire
Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026
Press releaseMar 9, 9:15 AM ETGlobe Newswire
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris
NewsFeb 3, 7:05 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Press releaseJan 8, 8:45 AM ETGlobe Newswire
Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones
NewsJan 2, 4:30 AM ETAvi Kapoor
Why Baidu Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
NewsNov 12, 6:11 AM ET
Earnings Scheduled For November 12, 2025
NewsNov 11, 2:03 PM ET
Biofrontera Earnings Preview
NewsNov 7, 7:52 AM ETVandana Singh
EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch
NewsAug 13, 4:32 AM ET
Earnings Scheduled For August 13, 2025
NewsAug 12, 1:02 PM ET
A Look at Biofrontera's Upcoming Earnings Report
Press releaseNov 22, 9:10 AM ETGlobe Newswire
Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note
NewsNov 12, 12:03 PM ET
Earnings Outlook For Biofrontera
NewsNov 1, 8:11 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
NewsNov 1, 8:11 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
NewsOct 31, 4:34 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
NewsOct 31, 12:34 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session
NewsAug 19, 5:18 AM ETAvi Kapoor
Why Xperi Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body

Transcript: Biofrontera Q2 2026 Earnings Conference Call

Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma

Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth

Transcript: Biofrontera Q1 2026 Earnings Conference Call

Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update

Earnings Scheduled For May 14, 2026

Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026

Biofrontera Q4 EPS $0.48 Beats $0.20 Estimate, Sales $17.100M Beat $16.146M Estimate

Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Earnings Scheduled For March 19, 2026

Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026

Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones

Why Baidu Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket

Earnings Scheduled For November 12, 2025

Biofrontera Earnings Preview

EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch

Earnings Scheduled For August 13, 2025

A Look at Biofrontera's Upcoming Earnings Report

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

Earnings Outlook For Biofrontera

12 Health Care Stocks Moving In Friday's Pre-Market Session

12 Health Care Stocks Moving In Friday's Pre-Market Session

12 Health Care Stocks Moving In Thursday's After-Market Session

12 Health Care Stocks Moving In Thursday's Intraday Session

Why Xperi Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket